Paper Details

  1. Home
  2. Paper Details

Efficacy and side effects of intermittent intravenous and oral doxercalciferol (1alpha-hydroxyvitamin D(2)) in dialysis patients with secondary hyperparathyroidism: a sequential comparison.

Author: AcchiardoS R, BishopC W, BowerJ D, ChesneyR W, CoburnJ W, DouglassL L, ElangovanL, FrazãoJ M, GoodmanW G, KelleyB J, KylloD M, LevineB S, MaungH M, MazessR B, NorrisK C, RobertsonJ A, RodriguezH J, RutkowskiM, SigalaJ F

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Controlled Clinical TrialA clinical trial that evaluates the effectiveness of a treatment by comparing a group that receives the intervention with a group that receives a placebo or standard treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).

Overview

Intravenous doxercalciferol (1alphaD(2)) effectively reduced parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. Compared to oral doxercalciferol, intravenous administration resulted in less frequent hypercalcemia and less increase in serum phosphorus levels.
Paper Details　
Original Abstract of the Article :
Most reports on the effectiveness and side effects of oral versus parenteral calcitriol or alfacalcidol in hemodialysis patients with secondary hyperparathyroidism show no advantage of parenteral treatment. The efficacy and safety of intravenous doxercalciferol (1alphaD(2)) were studied in hemodialy...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/11228177

データ提供：米国国立医学図書館（NLM）

Doxercalciferol: A Comparison of Intravenous and Oral Administration in Dialysis Patients

Navigating the treatment of secondary hyperparathyroidism in dialysis patients is often a challenging journey, often involving finding the right balance of effectiveness and safety. This research delves into the efficacy and side effects of doxercalciferol, a vitamin D analog, when administered intravenously and orally in patients with secondary hyperparathyroidism, a condition affecting parathyroid hormone levels in dialysis patients.

The authors conducted a sequential comparison study, evaluating the effectiveness of both intravenous and oral doxercalciferol in the same group of patients. Their findings suggest that both modes of administration effectively reduced parathyroid hormone levels. However, intravenous administration was associated with less frequent hypercalcemia and fewer increases in serum phosphorus levels, suggesting a potential advantage for patients prone to these complications.

Intravenous Doxercalciferol: A Potential Advantage for Certain Dialysis Patients

This study provides valuable insights into the administration of doxercalciferol in dialysis patients with secondary hyperparathyroidism. It suggests that intravenous administration might be a more favorable option for patients prone to hypercalcemia and hyperphosphatemia, offering a potential advantage in managing these complications. This research empowers clinicians to make informed decisions about doxercalciferol administration based on individual patient needs.

Navigating Dialysis Treatment: A Collaborative Effort

This study highlights the importance of individualized care in managing dialysis patients with secondary hyperparathyroidism. By understanding the nuances of doxercalciferol administration, clinicians can work collaboratively with patients to tailor treatment strategies that optimize effectiveness and minimize potential side effects. This research underscores the need for ongoing communication and collaboration between patients and healthcare providers in navigating the complexities of dialysis treatment.

Dr.Camel's Conclusion

This study delves into the intricate world of dialysis treatment, offering valuable insights into the administration of doxercalciferol in patients with secondary hyperparathyroidism. It's like finding a hidden oasis in the vast desert of dialysis research, providing a deeper understanding of the drug's effectiveness and potential side effects. The research emphasizes the importance of individualized care, empowering clinicians to make informed decisions based on patient needs, This study reminds us that navigating the challenges of dialysis treatment requires a collaborative effort between patients and healthcare providers, working together to find the best path to optimal health.

Date :
  1. Date Completed 2001-03-29
  2. Date Revised 2014-11-20
Further Info :

Pubmed ID

11228177

DOI: Digital Object Identifier

S0272638601579779

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.